ArticleLeukemia2005
Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies.
Article in Leukemia, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Non-interventional Multicentre Prospective Registry to Monitor the Incidence of Invasive Fungal Infections and to Monitor the Diagnostic and Therapeutic Management of Suspected Fungal-related Febrile Episodes in Patients With Malignant Hemopathies or Subjected to Haematopoietic Cell Transplant for the Treatment of Onco-haematological Diseases (HEMA E-CHART REGISTRY)
SEIFEM 2010: Epidemiological Survey on Possible Pre-Hospital Risk Factors for Developing Invasive Fungal Infections in Patients Affected by Acute Myeloid Leukemia
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Efficacy and safety of isavuconazole versus voriconazole for the treatment of invasive fungal infections: a meta-analysis with trial sequential analysis.BMC infectious diseases · 2025Pooled it
- Age difference of patients with and without invasive aspergillosis: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study.International journal of hematology · 2007Trial
- The Prevalence and Drug Susceptibility ofAntibiotics (Basel, Switzerland) · 2025Article
- Economic evaluation of treating invasive aspergillosis with isavuconazole, posaconazole and voriconazole in China.Future microbiology · 2025Article
- Diagnostic and Therapeutic Paradoxes in PCR-Positive, Histopathology-Negative CNS Aspergillosis in A Patient with HIV and Hodgkin Lymphoma.European journal of case reports in internal medicine · 2025Article
- Rate, Risk Factors, and Outcomes of Invasive Fungal Infections in Patients with Hematologic Malignancies.International journal of hematology-oncology and stem cell research · 2024Article
- Pathogenicity and virulence ofVirulence · 2023Review
- Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies.Scientific reports · 2023Article
- Article
- Host immune responses in the central nervous system during fungal infections.Immunological reviews · 2022Review
- Optimization of a Quantitative PCR Methodology for Detection of Aspergillus spp. and Rhizopus arrhizus.Molecular diagnosis & therapy · 2022Article
- Novel Treatment Approach for Aspergilloses by Targeting Germination.Journal of fungi (Basel, Switzerland) · 2022Review
- Diagnosis of Pneumonia Due to Invasive Molds.Diagnostics (Basel, Switzerland) · 2021Review
- Murine Models of Hematopoietic Cell Transplantation to Investigate Fungal Infections.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Genetic Risk Surveillance for Invasive Aspergillosis in Hematology Patients: A Prospective Observational Study.Infectious diseases and therapy · 2020Article
- Reconstituting NK Cells After Allogeneic Stem Cell Transplantation Show Impaired Response to the Fungal PathogenFrontiers in immunology · 2020Article
- Invasive fungal disease in humans: are we aware of the real impact?Memorias do Instituto Oswaldo Cruz · 2020Article
- Identification ofIranian journal of microbiology · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Risk factors for invasive aspergillosis (IA) are incompletely identified and may undergo changes due to differences in medical practice. A cohort of 189 consecutive, adult patients with neutropenia hospitalized in the hemato-oncology ward of the University hospital Berne between 1995 and 1999 were included in a retrospective study to assess risk factors for IA. In total, 45 IA cases (nine proven, three probable, 33 possible), 11 patients with refractory fever and 133 controls were analyzed. IA cases had more often acute leukemia or myelodysplastic syndrome (MDS) (88 vs 38%, P < 0.001) and a longer duration of neutropenia (mean 20.6 vs 9.9 days, P < 0.001). They also had fewer neutropenic episodes during the preceding 6 months (mean 0.42 vs 1.03, P < 0.001), that is, confirmed (82%) and probable (73%) IA occurred most often during the induction cycle. A short time interval ( < or = 14 days) between neutropenic episodes increased the risk of IA four-fold (P = 0.06). Bacteremia, however, was not related to the number of preceding neutropenic episodes. Therefore, neutropenic patients with leukemia or MDS have the highest risk of IA. The risk is highest during the first induction cycle of treatment and increases with short-time intervals between treatment cycles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.